VEGFC Antibody

What is VEGFC and what cellular functions does it regulate?

VEGFC (Vascular Endothelial Growth Factor C) is a member of the VEGF family with primary roles in lymphangiogenesis and angiogenesis in both normal homeostasis and pathological conditions. It functions primarily through binding to VEGFR-3 (FLT-4) and can also activate VEGFR-2 (KDR) receptors .

Methodologically important points:

• VEGFC binds to and activates VEGFR-3, predominantly expressed on lymphatic endothelial cells

• It also binds VEGFR-2, which is mainly expressed on blood vascular endothelial cells

• The protein plays crucial roles in the development and maintenance of circulatory and lymphatic systems

• In normal physiology, it regulates lymphatic vessel formation, endothelial cell proliferation, and migration

What are the most reliable methods for detecting VEGFC expression in tissue samples?

Several methodologies can be employed to detect VEGFC expression in tissue samples, each with specific advantages:

For optimal results, it's important to validate antibody specificity using appropriate controls and to optimize protocols for each specific tissue type .

How can researchers distinguish between different forms of VEGFC in experimental samples?

VEGFC undergoes extensive post-translational processing, making it important to distinguish between its different forms:

• The full-length VEGFC protein is approximately 47 kDa

• Processing generates multiple molecular weight species, commonly observed at 52 kDa, 34 kDa, and 13 kDa on Western blots

• The mature, fully processed form primarily activates VEGFR-3

Methodological approach:

• Use reducing conditions in Western blotting to better differentiate the forms

• Consider using antibodies targeting different epitopes when investigating processing

• For functional studies, note that the VEGFC mature form binds only to VEGFR-3, while unprocessed forms can bind both VEGFR-2 and VEGFR-3

• Use of recombinant proteins representing specific processed forms can serve as controls

What controls should be included when validating a new VEGFC antibody for research?

When validating a new VEGFC antibody, several controls should be incorporated:

For most rigorous validation, researchers should employ multiple detection methods (WB, IHC, IF) to confirm consistency across platforms .

How do VEGFC antibodies affect lymphatic vessel formation and function in inflammatory disease models?

VEGFC antibody therapies have shown significant effects on lymphatic vessels in inflammatory disease contexts:

Research findings demonstrate that antibody-mediated delivery of VEGFC to inflammatory sites leads to:

• Expansion of the lymphatic network in inflamed tissues

• Improved lymphatic clearance function

• Reduction of inflammation-associated edema

• Decreased inflammatory cell infiltration

In a chronic skin inflammation model, F8-VEGFC (a fusion protein consisting of VEGFC fused to the F8 antibody targeting EDA fibronectin):

• Induced marked expansion of the lymphatic network

• Alleviated inflammation-associated skin edema

• Improved lymphatic clearance function

• Reduced inflammatory cell infiltration compared to control groups

Similar effects were observed in inflammatory bowel disease models, where F8-VEGFC:

• Accumulated specifically in inflamed colon tissue

• Reduced clinical and histological signs of inflammation

• Expanded the lymphatic vascular network

• Decreased inflammatory cytokine expression

Importantly, long-term studies have shown that targeted delivery of VEGF-C leads to long-lasting lymphatic expansion and provides protection against repeated inflammatory challenges .

What is the mechanism of action of VEGFC antibodies in treating hematological malignancies?

VEGFC antibodies have shown significant therapeutic potential in acute myeloid leukemia (AML) through several mechanisms:

• VEGFC antibody therapy enforces myelocytic differentiation of clonal CD34+ AML blasts

• Treatment of CD34+ AML blasts with VEGFC antibodies reduces expansion potential by 30-50%

• The mechanism involves enhancement of differentiation via FOXO3A suppression

• VEGFC antibodies inhibit MAPK/ERK proliferative signals in leukemic cells

In vivo studies with a systemic humanized AML mouse model demonstrated that:

• VEGFC antibody therapy accelerated leukemia cell differentiation

• Results define a regulatory function of VEGFC in CD34+ AML cell fate decisions via FOXO3A

• This approach represents a novel differentiation therapy for AML patients

This is particularly significant as high VEGFC expression has been identified as an independent prognostic factor in AML, associated with decreased complete remission rates and reduced survival .

How do the effects of anti-VEGFC antibodies differ between targeting VEGFR-2 versus VEGFR-3 pathways?

VEGFC can activate both VEGFR-2 and VEGFR-3 receptors, with distinct downstream effects:

Research findings indicate:

• Antibodies specifically blocking VEGFC-VEGFR3 interaction (e.g., VEGF-C156Ser mutant) can selectively activate VEGFR-3 without VEGFR-2 effects

• Studies comparing F8-VEGF-C and F8-VEGF-C156Ser showed that VEGFR-3-specific activation retains prolymphangiogenic effects

• VEGFC antibodies targeting both receptors may induce some transient blood vessel permeability, but typically don't cause significant blood vessel proliferation

• In cancer models such as renal cell carcinoma, VEGFC antibodies inhibit VEGFR3 signaling and suppress both angiogenesis and lymphangiogenesis

This distinction is crucial for therapeutic development, as VEGFR-3-specific targeting may provide lymphatic system benefits while minimizing potential vascular side effects.

What are the methodological considerations when using VEGFC antibodies for therapeutic applications versus diagnostic detection?

The applications of VEGFC antibodies for therapy versus detection require different methodological approaches:

Therapeutic Applications:

• Antibody format selection is critical (diabody format shows improved tissue penetration and faster clearance while maintaining good target-site retention)

• Targeting strategies must be considered (e.g., F8 antibody targets extradomain A of fibronectin, allowing specific delivery to inflamed tissues)

• Dosing regimens need optimization (single low-dose of VEGFC mRNA-LNPs can induce durable lymphatic growth)

• Route of administration affects tissue targeting (intradermal, intraperitoneal, intratracheal, or intramuscular administration results in organ-specific effects)

• Potential immune reactions to antibody constructs must be monitored

Diagnostic Applications:

• Sensitivity and specificity parameters differ (detection requires high specificity but not necessarily therapeutic efficacy)

• Multiple application compatibility is important (WB, IF/ICC, IHC, ELISA)

• Cross-reactivity with different species must be characterized

• Epitope selection affects which forms of VEGFC are detected (full-length vs. processed forms)

• Storage and handling conditions impact antibody performance (typically store at -20°C with 0.02% sodium azide and 50% glycerol)

How can researchers evaluate the efficacy of VEGFC antibody therapy in preclinical cancer models?

Evaluating VEGFC antibody efficacy in preclinical cancer models requires a multi-parameter approach:

Key Assessment Parameters:

• Tumor Growth Inhibition:

  • Measure tumor volume/weight over time

  • Compare treatment groups (e.g., VEGFC antibody alone vs. combination with anti-angiogenic agents)

• Lymphatic/Vascular Changes:

  • Quantify lymphatic vessel density using markers like LYVE-1 and Podoplanin

  • Assess blood vessel density using markers like CD31 and vWF

  • Evaluate vessel functionality through tracer uptake studies

• Cellular Mechanisms:

  • Examine cell proliferation via EdU or Ki67 staining

  • Assess migration through in vitro wound healing assays

  • Measure receptor activation (VEGFR3 phosphorylation) via ELISA

• Molecular Pathways:

  • Analyze downstream signaling (MAPK/ERK, FOXO3A)

  • Measure cytokine/growth factor expression profiles

  • Evaluate immune cell infiltration using markers for specific cell populations

In renal cell carcinoma models, for example, researchers demonstrated that:

• 1E9 antibodies decreased tumor growth and weight

• Therapeutic efficacy was enhanced when combined with anti-VEGF antibody bevacizumab

• The mechanism involved inhibition of VEGFR3 signaling and NRP2 signaling

For comprehensive evaluation, both in vitro (cell proliferation, migration, receptor activation) and in vivo (tumor growth, vascular changes) assessments should be integrated.

What are the technical challenges in developing fusion proteins incorporating VEGFC for targeted therapy?

Developing VEGFC fusion proteins presents several technical challenges that researchers must address:

Production and Purification:

• Expression systems must maintain protein folding and post-translational modifications

• VEGFC requires proper folding for receptor binding activity

• Purification methods must preserve biological activity while removing contaminants

Targeting Moiety Selection:

• Antibody fragment selection affects tissue penetration and clearance

• Linker design between VEGFC and targeting moiety impacts stability and function

• Target antigen selection determines specificity (e.g., F8 antibody targeting EDA domain of fibronectin)

Stability and Pharmacokinetics:

• Fusion proteins may have altered half-life compared to native proteins

• Immunogenicity risks must be assessed and minimized

• Biodistribution studies with radiolabeled proteins are essential to confirm targeting

Functional Validation:

• Fusion proteins must retain both targeting specificity and VEGFC biological activity

• In vitro binding assays must confirm target antigen affinity

• Biological activity testing (e.g., VEGFR3 activation) is essential

In successful examples like F8-VEGFC, researchers:

• Genetically linked human VEGFC to the F8 diabody

• Confirmed that fusion proteins retained high-antigen affinity

• Validated that prolymphangiogenic effects were maintained in vitro and in vivo

What are the optimal experimental conditions for evaluating VEGFC antibody specificity?

Establishing optimal conditions for VEGFC antibody specificity evaluation requires a systematic approach:

Western Blot Optimization:

Immunostaining Optimization:

• For IHC: Test multiple antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0)

• For IF/ICC: Fixation protocol affects epitope accessibility (4% paraformaldehyde recommended)

• Use positive control tissues/cells with known VEGFC expression

Validation Approaches:

• Compare multiple VEGFC antibodies targeting different epitopes

• Include VEGFC knockdown/knockout controls

• Test cross-reactivity with related proteins (VEGFA, VEGFB, VEGFD)

• Perform peptide competition assays to confirm specificity

• Evaluate specificity across multiple applications (WB, IHC, IF)

How can researchers distinguish between VEGFC-mediated effects and other angiogenic/lymphangiogenic pathways?

Differentiating VEGFC-specific effects from other angiogenic/lymphangiogenic pathways requires careful experimental design:

Experimental Strategies:

• Receptor-Specific Blockade:

  • Use VEGFR3-specific blocking antibodies alongside VEGFC antibodies

  • Compare with VEGFR2 blockade to differentiate effects

  • Employ VEGF-C156Ser mutant that only activates VEGFR-3

• Genetic Approaches:

  • Generate VEGFC knockout models using CRISPR/Cas9

  • Create NRP2 knockout cells to assess co-receptor dependence (e.g., 786-O_#NRP2-KO cells)

  • Develop receptor-specific knockout models

• Signaling Pathway Analysis:

  • Examine downstream pathways (MAPK/ERK, FOXO3A)

  • Compare signaling signatures between VEGFC and other factors

  • Use specific pathway inhibitors to isolate effects

• Comparative Studies:

  • Test multiple VEGF family members in parallel

  • Include relevant controls (e.g., VEGFA stimulation vs. VEGFC)

  • Assess additive or synergistic effects with combination treatments

Research findings demonstrate that:

• 1E9 antibodies specifically inhibit VEGFR3 signaling, not VEGFR2

• These antibodies affect VEGFC-stimulated endothelial cells but not those stimulated by other factors

• In cancer models, combining anti-VEGFC with anti-VEGF therapy (bevacizumab) shows enhanced efficacy, indicating distinct but complementary pathways

What methods provide the most reliable quantification of lymphatic vessel changes following VEGFC antibody treatment?

Quantifying lymphatic vessel changes following VEGFC antibody treatment requires robust methodologies:

Imaging-Based Quantification:

• Immunostaining with lymphatic markers (LYVE-1, Podoplanin, Prox1) for vessel identification

• Whole-mount imaging for 3D visualization of lymphatic networks

• Confocal microscopy for high-resolution analysis of vessel morphology

• Automated image analysis for unbiased quantification of vessel parameters

Functional Assessment:

• Fluorescent tracer injection and clearance measurements

• Evans blue dye to assess tissue edema

• Near-infrared imaging with indocyanine green to visualize lymphatic flow

• Intravital microscopy for real-time visualization of lymphatic function

Key Parameters to Quantify:

Studies have shown that:

• EdU incorporation assay can effectively measure lymphatic endothelial cell proliferation (mitotic index)

• Both the number and fraction of EdU positive nuclei of lymphatic endothelial cells increase after VEGFC treatment

• Long-term studies (up to 75 days) show that newly formed lymphatic vessels maintain normal morphology and function

How should researchers interpret conflicting data on VEGFC expression and its correlation with disease outcomes?

Interpreting conflicting data on VEGFC expression and disease outcomes requires careful consideration of multiple factors:

Key Considerations:

• Disease Stage Specificity:

  • VEGFC plays differential roles depending on cancer stage

  • In early-stage clear cell renal cell carcinoma (ccRCC), VEGFC can be a marker of good prognosis

  • In metastatic ccRCC, VEGFC is associated with poor prognosis

• Tissue Context Dependencies:

  • Normal lymphatic networks during tumor initiation may activate anti-tumor immune responses

  • In advanced stages, VEGFC-induced lymphatic networks enhance tumor cell dissemination

  • Local tissue microenvironment affects VEGFC signaling outcomes

• Methodological Variations:

  • Different antibodies may detect different forms of VEGFC

  • Variations in sample collection, processing, and analysis techniques

  • Thresholds used for "high" versus "low" expression classification

• Biological Complexity:

  • VEGFC interacts with multiple receptors (VEGFR-2, VEGFR-3, NRP2)

  • Post-translational processing affects activity

  • Compensatory mechanisms may exist in different contexts

Reconciliation Approaches:

• Stratify analyses by disease stage, grade, and molecular subtype

• Employ multiple detection methods to confirm expression patterns

• Consider the entire signaling axis (ligand, receptors, downstream effectors)

• Integrate functional studies with expression data

• Perform meta-analyses across multiple studies with standardized methodologies

Research has demonstrated this complexity in renal cell carcinoma, where VEGFC-directed therapies appear relevant only for metastatic disease despite varying prognostic associations in different disease stages .

What are the most effective protocols for developing and validating a custom anti-VEGFC antibody?

Developing and validating a custom anti-VEGFC antibody requires a systematic multi-step approach:

Antibody Development Process:

• Antigen Design and Preparation:

  • Select specific domains of VEGFC for immunization (e.g., mature form that binds only to VEGFR3)

  • Create fusion proteins (e.g., GST-VEGFC) for immunization

  • Purify antigen using appropriate methods (e.g., FPLC)

• Immunization and Hybridoma Creation:

  • Immunize mice with the selected VEGFC antigen

  • Screen isolated antigen-binding clones for:

    • Binding affinity to VEGFC

    • Neutralization capacity

    • Production yield

• Antibody Production and Engineering:

  • For chimeric antibodies, sequence selected hybridomas

  • Subclone variable light and heavy chains into expression vectors

  • Stably transfect cells (e.g., CHO cells) for production

Validation Protocol:

• Binding Specificity:

  • ELISA against purified VEGFC and related proteins

  • Western blot against recombinant VEGFC and cell lysates

  • Immunoprecipitation followed by mass spectrometry

• Functional Characterization:

  • VEGFR3 phosphorylation assay (e.g., using ELISA)

  • Cell proliferation assays with VEGFC-responsive cells (HuVECs, LECs)

  • Migration assays to assess inhibition of VEGFC-stimulated cell movement

• In Vivo Validation:

  • Pharmacokinetics and biodistribution studies

  • Target engagement in relevant tissues

  • Efficacy in disease models (e.g., cancer, inflammation)

In the successful development of the 1E9 antibody, researchers:

• Selected one hybridoma producing specific anti-VEGFC monoclonal antibodies

• Sequenced and subcloned it into expression vectors with human IgG1 constant domains

• Validated that these antibodies inhibited VEGFR3 signaling and cell proliferation/migration

• Confirmed efficacy in renal cell carcinoma models

How can researchers optimize VEGFC antibody-based therapeutic delivery systems for specific disease applications?

Optimizing VEGFC antibody-based therapeutic delivery requires tailoring approaches to specific disease contexts:

Targeting Strategies:

• Disease-Specific Targeting Moieties:

  • For inflammatory diseases: Use antibodies targeting inflammation markers (e.g., F8 antibody targeting EDA domain of fibronectin)

  • For cancer: Consider tumor-specific antigens or tumor vasculature markers

  • For lymphedema: Target lymphatic vessel components or interstitial markers

• Fusion Protein Design:

  • Optimize linker length and composition between targeting moiety and VEGFC

  • Consider single-chain variable fragments or diabody formats for improved tissue penetration

  • Engineer stability and half-life modifications

Delivery Optimization:

Formulation Considerations:

• For protein-based therapeutics: Stability, aggregation prevention, and immunogenicity

• For nucleic acid approaches: Lipid nanoparticle composition and nucleoside modification

• Dosing regimen optimization (single vs. multiple administrations)

Research shows that a single low-dose of VEGFC mRNA-LNPs induced durable lymphatic growth, while F8-VEGFC fusion proteins provided targeted delivery to inflammation sites with reduced systemic effects .

What factors affect the reproducibility of VEGFC antibody-based assays in different experimental systems?

Several factors can impact the reproducibility of VEGFC antibody-based assays across different experimental systems:

Technical Variables:

• Antibody Characteristics:

  • Lot-to-lot variability affecting binding affinity/specificity

  • Storage conditions and freeze-thaw cycles

  • Antibody format (monoclonal vs. polyclonal, IgG subclass)

  • Host species and production method

• Sample Preparation:

  • Protein extraction methods (lysis buffers, protease inhibitors)

  • Fixation protocols for tissue/cells affecting epitope accessibility

  • Antigen retrieval methods for IHC/IF (buffer type, pH, incubation time)

  • Reducing vs. non-reducing conditions for Western blot

• Detection Systems:

  • Secondary antibody selection and optimization

  • Signal amplification methods

  • Imaging parameters and analysis algorithms

Biological Variables:

• VEGFC Expression and Processing:

  • Cell type-specific processing of VEGFC

  • Variation in VEGFC isoform expression

  • Growth conditions affecting VEGFC levels

  • Species differences in VEGFC structure and epitopes

• Cell/Tissue Context:

  • Matrix effects in different sample types

  • Endogenous binding proteins affecting accessibility

  • Disease state altering protein modifications or localization

Optimization Strategies:

• Include consistent positive controls across experiments

• Standardize protocols with detailed SOPs

• Validate antibodies in each experimental system

• Use multiple antibodies targeting different epitopes

• Include technical and biological replicates

• Normalize to appropriate internal controls

For Western blotting, recommended dilutions range from 1:500-1:5000, but optimal conditions should be determined for each application and sample type .

How might combination therapies involving VEGFC antibodies and other immunomodulatory agents enhance therapeutic outcomes?

Combination therapies incorporating VEGFC antibodies with other immunomodulatory agents show significant potential for enhanced efficacy:

Promising Combinations:

• VEGFC Antibodies + Anti-angiogenic Agents:

  • Research shows combining anti-VEGFC antibodies (1E9) with bevacizumab (anti-VEGF) more efficiently inhibits renal cell carcinoma growth than either treatment alone

  • Mechanistic rationale: Simultaneously targeting blood and lymphatic vessel formation blocks complementary tumor support systems

• VEGFC Antibodies + Immune Checkpoint Inhibitors:

  • Potential to combine lymphatic modulation with T-cell activation

  • VEGFC-induced lymphatic changes may improve immune cell trafficking and antigen presentation

  • Could enhance response rates in immunotherapy-resistant tumors

• VEGFC Antibodies + Cytokine Therapies:

  • Integration with IL-2 or IL-10 fusion proteins that have shown promise in cancer and inflammatory diseases

  • Complementary mechanisms addressing both lymphatic function and immune cell activity

Mechanistic Considerations:

• VEGFC antibody treatment alters the tumor microenvironment and may enhance immunotherapy access

• Improved lymphatic function can enhance immune cell trafficking to lymph nodes

• Reduced tissue edema may improve drug delivery to target tissues

• Decreased inflammatory cell density may reduce immunosuppressive signals

Emerging Research Directions:

• Targeting VEGFC in combination with chemotherapy to reduce therapy-induced lymphedema

• Integration with radiation therapy to address radiation-induced fibrosis and lymphatic damage

• Sequential therapy approaches to optimize timing of lymphatic modulation and immune activation

Studies have demonstrated that BVZ (bevacizumab) treatment increases VEGFC production by cancer cells, providing a strong rationale for combination approaches targeting both pathways .

What novel delivery systems are being developed to enhance the efficacy of VEGFC antibody therapies?

Innovative delivery systems are advancing the efficacy of VEGFC antibody therapies:

Nucleic Acid-Based Approaches:

• Nucleoside-modified VEGFC mRNA encapsulated in lipid nanoparticles (mRNA-LNPs) shows remarkable efficacy

• A single low-dose administration induces durable, organ-specific lymphatic growth

• This approach outperforms recombinant VEGFC protein treatment in lymphangiogenic effect

• FPLC-purified mRNA provides enhanced stability and reduced immunogenicity

Antibody-Directed Delivery Systems:

• F8-VEGFC fusion proteins target the EDA domain of fibronectin in inflamed tissues

• The diabody format improves tissue penetration and provides faster clearance while maintaining good target-site retention

• Biodistribution studies with radiolabeled fusion proteins confirm specific accumulation at target sites

Organ/Tissue-Specific Administration Routes:

Emerging Delivery Technologies:

• Sustained-release formulations to prolong VEGFC effects

• Stimuli-responsive systems triggered by disease-specific conditions

• Combinatorial delivery platforms incorporating multiple therapeutic agents

• Cell-based delivery systems using engineered cells to produce VEGFC at target sites

Research demonstrates that these advanced delivery systems can induce long-lasting lymphatic expansion and provide protection against repeated inflammatory challenges, suggesting potential for chronic disease management .

How might VEGFC antibody technologies contribute to personalized medicine approaches in cancer and inflammatory diseases?

VEGFC antibody technologies hold significant potential for advancing personalized medicine approaches:

Biomarker-Guided Treatment Selection:

• VEGFC expression levels serve as prognostic indicators in multiple cancer types

  • High VEGFC expression predicts adverse prognosis in acute myeloid leukemia (AML)

  • VEGFC is a marker of good prognosis in low-grade ccRCC but indicates poor prognosis in metastatic disease

• Patient stratification based on VEGFC expression patterns could identify appropriate candidates for anti-VEGFC therapy

Disease-Specific Targeting Strategies:

• Different disease contexts require tailored approaches:

  • For inflammatory diseases: Target EDA fibronectin with F8-VEGFC fusion proteins

  • For metastatic cancers: Direct VEGFC neutralization with 1E9-type antibodies

  • For lymphedema: VEGFC supplementation via mRNA-LNP delivery

Precision Monitoring:

• Lymphatic imaging technologies can track individual responses to VEGFC-targeted therapies

• Biofluid analysis of VEGFC levels during treatment may guide dosing adjustments

• Multi-parameter assessment of lymphatic function could identify early responders

Combinatorial Personalized Approaches:

• Integration with genetic profiling (e.g., VEGFR3 mutations in lymphedema patients)

• Tailored combination therapies based on individual immune profiles

• Patient-specific delivery route selection based on disease localization

Research demonstrates that VEGFC antibody therapy drives differentiation of AML blasts, reducing expansion potential by 30-50% and enhancing differentiation through specific molecular pathways , suggesting potential for precision applications in hematological malignancies.

The development of multiple VEGFC-targeting modalities (neutralizing antibodies, fusion proteins, mRNA delivery) provides a versatile toolkit for personalized therapy selection based on individual disease characteristics and therapeutic goals.